7,060 Axsome Therapeutics, Inc. $AXSM Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 11.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 53,532 shares of the company’s stock after selling 7,060 shares during the quarter. Russell Investments Group Ltd.’s holdings in Axsome Therapeutics were worth $9,871,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth about $759,695,000. ABS Investment Management LLC acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at approximately $171,339,000. Bank of America Corp DE acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at approximately $110,756,000. First Trust Advisors LP grew its holdings in Axsome Therapeutics by 1,230.2% in the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after buying an additional 534,066 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its position in Axsome Therapeutics by 12.9% in the 3rd quarter. Pictet Asset Management Holding SA now owns 481,524 shares of the company’s stock worth $88,789,000 after buying an additional 54,997 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AXSM shares. Guggenheim cut their price target on Axsome Therapeutics from $275.00 to $250.00 and set a “buy” rating for the company in a report on Tuesday, November 3rd. Truist Financial raised their price objective on shares of Axsome Therapeutics from $200.00 to $285.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Piper Sandler lowered their price objective on shares of Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a research note on Monday, October 26th. HC Wainwright reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, September 25th. Finally, Wells Fargo & Company reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $266.21.

View Our Latest Stock Analysis on AXSM

Axsome Therapeutics Stock Down 4.7%

NASDAQ AXSM opened at $129.36 on Friday. Axsome Therapeutics, Inc. has a twelve month low of $123.00 and a twelve month high of $260.19. The stock has a market cap of $6.80 billion, a PE ratio of -42.27 and a beta of 0.86. The firm has a 50-day simple moving average of $163.75 and a 200 day simple moving average of $195.47. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.34 and a current ratio of 1.42.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.38. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The firm had revenue of $259.69 million for the quarter, compared to analyst estimates of $249.19 million. During the same period in the previous year, the company posted ($0.94) earnings per share. The company’s quarterly revenue was up 51.9% compared to the same quarter last year. On average, research analysts forecast that Axsome Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares in the company, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Profile

(Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Further Reading

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.